Mouse Anti-Monkey IgG-FITC

Cat. No.
4700-02  
Size
0.5 mg  
Price (USD)
$210.00 
Clone SB108a
Isotype Mouse (BALB/c) IgG1κ
Isotype Control Mouse IgG1-FITC
Immunogen Rhesus IgG
Specificity Rhesus and cynomolgus IgG
Minimal reactivity to human and rabbit immunoglobulins, goat IgG, and mouse, rat, hamster, guinea pig, sheep, donkey, bovine, horse, porcine, feline, and chicken serum
Format/Conjugate FITC (Fluorescein)
Buffer Formulation Phosphate buffered saline containing < 0.1% sodium azide
Concentration 0.5 mg/mL
Volume 1.0 mL
Storage & Handling 2-8°C; Avoid exposure to light
Please refer to product specific SDS
Applications
Applications for relevant formats of this clone include -
ELISA – Quality tested 1-8
FLISA – Quality tested
Flow Cytometry – Reported in literature 9
Western Blot – Reported in literature 10
Recommended Dilutions Please refer to product specific Technical Bulletin
RRID AB_2796067
Related Products (8)
References
1. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543-7. (ELISA)
2. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012;7(5):e37019. (ELISA)
3. Ferraro B, Talbott KT, Balakrishnan A, Cisper N, Morrow MP, Hutnick NA, et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect Immun. 2013;81:3709-20. (ELISA)
4. Padte NN, Boente-Carrera M, Andrews CD, McManus J, Grasperge BF, Gettie A, et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One. 2013;8(10):e78407. (ELISA)
5. Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, et al. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine. 2015;33:2086-95. (ELISA)
6. Bolton DL, Pegu A, Wang K, McGinnis K, Nason M, Foulds K, et al. Human immunodeficiency virus type 1 monoclonal antibodies suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-associated viral reservoirs. J Virol. 2015;90:1321-32. (ELISA)
7. Yang Z, Wang H, Salcedo TW, Suchard SJ, Xie JH, Schneeweis LA, et al. Integrated pharmacokinetic/pharmacodynamic analysis for determining the minimal anticipated biological effect level of a novel anti-CD28 receptor antagonist BMS-931699. J Pharmacol Exp Ther. 2015;355:506-15. (ELISA)
8. Kutzler MA, Wise MC, Hutnick NA, Moldoveanu Z, Hunter M, Reuter MA, et al. Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. Mucosal Immunol. 2016;9:13-23. (ELISA)
9. Guo J, Zuo T, Cheng L, Wu X, Tang J, Sun C, et al. Simian immunodeficiency virus infection evades vaccine-elicited antibody responses to V2 region. J Acquir Immune Defic Syndr. 2015;68:502-10. (FC)
10. Parks CL, Koff WC, inventors; International AIDS Vaccine Initiative, assignee. Transgenic Vero-CD4-CCR5 cell line. United States patent applicaton publication US 2017/0266272 A1. 2017 Sep21. (WB)